Buckingham Research Downgrades Salix Pharmaceuticals (SLXP) to Neutral
Tweet Send to a FriendGet Alerts SLXP Hot Sheet
Price: $60.39 +1.17%
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade SLXP Now!
Buckingham Research downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $53.75 yesterday, with a 52 week range of $25.64-$53.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $53.75 yesterday, with a 52 week range of $25.64-$53.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Baird Downgrades Titan Machinery (TITN) to Neutral
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Create E-mail Alert Related Categories
DowngradesRelated Entities
Buckingham Research
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
